HIV ReportsPharmacokinetics of Nevirapine in HIV and Tuberculosis–coinfected Children Receiving Antiretroviral Fixed-dose Combination Tablets While Receiving Rifampicin-containing Tuberculosis Treatment and After Rifampicin DiscontinuationPrasitsuebsai, Wasana MD*; Cressey, Tim R. PhD†‡; Capparelli, Edmund PharmD§; Vanprapar, Nirun MD*; Lapphra, Keswadee MD*; Chokephaibulkit, Kulkanya MD*Author Information *Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand †Program for HIV Prevention and Treatment (IRD URI 174), Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand ‡Department of Immunology & Infectious Diseases, Harvard School of Public Health, Boston, MA §Department of Pediatric Pharmacy and Drug Discovery, University of California, San Diego, CA Accepted for publication November 2, 2011. Supported by the Thai Commission on Higher Education. The authors have no other funding or conflicts of interest to disclose. Address for correspondence: Kulkanya Chokephaibulkit, MD, Division of Infectious Diseases, 8th floor HRH Princess Bldg, Siriraj Hospital, Prannok Rd, Bangkok-noi, Bangkok, Thailand, 10700. E-mail: email@example.com. The Pediatric Infectious Disease Journal: April 2012 - Volume 31 - Issue 4 - p 389-391 doi: 10.1097/INF.0b013e3182401c41 Buy Metrics Abstract We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis–coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation. The median age (range) was 9.7 (4.4–11.7) years. The nevirapine area under the concentration versus time curve from 0 to12 hours and trough concentration with rifampicin were 85.3 (40.5–170.7) mg.h/mL and 6.4 (3.00–13.27) mg/mL, respectively, providing adequate exposure. © 2012 Lippincott Williams & Wilkins, Inc.